Related Experiment Video

Updated: May 7, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy

Caroline B Madsen1, Hans H Wandall, Anders Elm Pedersen

  • 1Department of Cellular and Molecular Medicine, Copenhagen Center for Glycomics and.

Immunopharmacology and Immunotoxicology
|September 26, 2013
PubMed

Insights

Targeting cancer-specific Tn-MUC1 (GalNAc-α-MUC1) with antibodies shows promise for passive immunotherapy. This approach may reduce cross-reactivity with normal tissues, enhancing treatment safety and efficacy in breast cancer.

Area of Science:

  • Oncology
  • Immunology
  • Glycobiology

Background:

  • MUC1 is a key target in cancer immunotherapy, but antibodies targeting its glycan or peptide components can cross-react with normal tissues.
  • Developing antibodies against cancer-specific MUC1 epitopes is crucial to improve immunotherapy safety and efficacy.

Purpose of the Study:

  • To investigate the potential of targeting cancer-specific MUC1 glycopeptide epitopes for passive cancer immunotherapy.
  • To evaluate the efficacy of a monoclonal antibody against the Tn-MUC1 (GalNAc-α-MUC1) antigen.

Main Methods:

  • Development and characterization of monoclonal antibodies targeting specific MUC1 glycopeptide epitopes.
  • Assessment of antibody-induced antibody-dependent cell-mediated cytotoxicity (ADCC) in breast cancer cell lines.

Main Results:

  • A monoclonal antibody targeting the immunodominant Tn-MUC1 (GalNAc-α-MUC1) antigen was generated.
  • This antibody demonstrated the ability to induce ADCC in breast cancer cell lines.

Conclusions:

  • Targeting combined glycopeptide epitopes on MUC1, such as Tn-MUC1, represents a feasible strategy for passive cancer immunotherapy.
  • This approach holds potential for developing safer and more effective cancer treatments by minimizing off-target effects.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.